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Variceal bleeding accounts for 70% of upper gastrointestinal bleeding 
episodes in patients with portal hypertension.1 It significantly 
influences the natural history of compensated alcgaoholic cirrhosis 
because a quarter of initial bleeding episodes are fatal, and as many 
as 70% of survivors, if inadequately treated, have recurrent variceal 
bleeding.2 Endoscopic control of bleeding is widely used as the 
emergency treatment of choice for actively bleeding oesophageal 
varices.3-5 Although treatment advances have reduced overall 
mortality,6,7 uncontrolled or recurrent bleeding from varices and 
the consequences of ensuing liver decompensation remain the most 
common cause of early death in alcoholic cirrhotic patients.8 
Despite the general use of endoscopic therapy, there are few robust 
and validated data on the efficacy of endoscopic control of the 
index variceal bleed, the frequency of early rebleeding, and survival 
following the initial bleed in alcoholic cirrhotic patients.6-8 Published 
results are inconsistent and conflicting because of small sample sizes, 
referral bias, dissimilar study end-points, and differences in patient 
selection, methods and techniques of endoscopic intervention, 
and the precise definition of rebleeding.4,9 There is consensus that 
assessment of intervention efficacy in cirrhotic patients with portal 
hypertension and bleeding oesophageal varices should be based on 
the control of bleeding and the risks of rebleeding and death as the 3 
major outcomes.10,11 We aimed to evaluate the efficacy of endoscopic 
intervention in achieving control of acute variceal bleeding and 
preventing rebleeding and death during the first hospital admission 
in a large cohort of consecutively treated alcoholic cirrhotic patients 
with bleeding oesophageal varices.
Methods
Consecutive adult alcoholic cirrhotic patients with endoscopically 
proven acute oesophageal variceal bleeding who were admitted to 
a specialist surgical gastroenterology unit between January 1984 
and August 2011 were assessed. These patients received their 
first emergency and subsequent endoscopic interventions in our 
unit. Data were recorded prospectively on a standard pro forma 
and entered into a database maintained by a dedicated research 
assistant. The diagnosis of cirrhosis was established by liver function 
tests, ultrasound and portal Doppler assessment, liver biopsy and, 
in selected patients, hepatic vein wedge pressure measurements. 
Cirrhosis was considered to be alcohol-related if patients gave a 
history of sustained heavy alcohol consumption over several years 
with corroborative liver histological evidence and exclusion of other 
causes. The study was approved by the departmental and institutional 
ethics and research committees. 
During the 332-month study period, 693 consecutive adult patients 
were treated for oesophageal variceal bleeding; 245 had non-alcoholic 
causes of portal hypertension and were excluded; 469 had portal 
hypertension caused by alcohol-induced cirrhosis. Of these, 21 
patients were not included because they also had positive hepatitis 
B or C viral markers. This study is based on data in the remaining 
448 patients with alcoholic cirrhosis and proven oesophageal variceal 
bleeding who received endoscopic intervention for bleeding.
Control of variceal bleeding was evaluated at 2 time points: initial 
control during the first presentation and rebleeding during the index 
hospital admission. The primary clinical endpoints were: (i) failure to 
control variceal bleeding during the initial endoscopic intervention, 
(ii) rebleeding after initial endoscopic control, and (iii) mortality 
during the initial hospital admission. 
Injection sclerotherapy was used as described previously.12,13 Both 
diagnostic endoscopy and injection sclerotherapy were performed 
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Background. Variceal bleeding (VB) is the leading cause of death 
in cirrhotic patients with oesophageal varices. We evaluated the 
efficacy of emergency endoscopic intervention in controlling acute 
variceal bleeding and preventing rebleeding and death during the 
index hospital admission in a large cohort of consecutively treated 
alcoholic cirrhotic patients after a first variceal bleed.
Methods. From January 1984 to August 2011, 448 alcoholic 
cirrhotic patients (349 men, 99 women; median age 50 years) 
with VB underwent endoscopic treatments (556 emergency, 249 
elective) during the index hospital admission. Endoscopic control 
of initial bleeding, variceal rebleeding and survival after the first 
hospital admission were recorded. 
Results. Endoscopic intervention alone controlled VB in 394 
patients (87.9%); 54 also required balloon tamponade. Within 24 
hours 15 patients rebled; after 24 hours 61 (17%, n=76) rebled; 
and 93 (20.8%) died in hospital. No Child-Pugh (C-P) grade A 
patients died, while 16 grade B and 77 grade C patients died. 
Mortality increased exponentially as the C-P score increased, 
reaching 80% when the C-P score exceeded 13.
Conclusion. Despite initial control of variceal haemorrhage, 1 
in 6 patients (17%) rebled during the first hospital admission. 
Survival (79.2%) was influenced by the severity of liver failure, 
with most deaths occurring in C-P grade C patients.
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using a fibreoptic endoscope (GIF 1T20 or K10, Olympus Corp) 
during the first decade of the study and video-endoscopy during the 
last decade. The sclerosant, 5% ethanolamine oleate, was injected 
using a combined intra- and paravariceal technique.12,13
The original single-shot endoscopic variceal banding device (C R 
Bard, Tewksbury, MA) was used initially when banding was introduced 
in 1994.13,14 On average, a total of 6 bands were applied during the 
initial endoscopic banding session, and progressively fewer bands 
were required during subsequent sessions as the varices decreased 
in size. The technical disadvantage of the single band applicator is 
that the endoscope has to be removed and reinserted repeatedly 
with a new band attached for each individual variceal ligation. The 
introduction of the newly designed multiband ligator overcame these 
disadvantages with 6 mounted bands which are individually activated 
by a drawstring attached to a trigger unit positioned in the biopsy 
channel port of the endoscope, allowing repeated firing of the bands 
and obviating the need for an overtube.14,15 Equipment used included 
either an Olympus XQ 240 or 260 endoscope, and a 6-shooter multi-
band ligator (Wilson-Cook Medical).
Time zero was defined as the time of hospital admission. Failure to 
control bleeding was defined as continued bleeding despite endoscopic 
injection and the use of balloon tamponade. Rebleeding was defined 
as any episode of upper gastrointestinal bleeding that occurred after 
the initial bleed had been successfully controlled by endoscopic 
therapy. Rebleeding was treated by urgent endoscopy and endoscopic 
control of bleeding if it originated in patent residual varices. Patient 
data were evaluated only during the initial hospital admission. All 
bleeding and complications related to endoscopic intervention and 
deaths during this period were recorded. Rebleeding was evaluated 
in 3 specific categories: (i) uncontrolled bleeding during the index 
scope with failure of endoscopic treatment, (ii) continued or early 
rebleeding within 24 hours of the initial endoscopic treatment, 
requiring a second endoscopy, and (iii) rebleeding more than 24 
hours after the index endoscopic treatment.
Data were stored on a spreadsheet registry and analysed using 
STATA 11.0 (StataCorp). Associations between categorical variables 
were analysed using Pearson’s chi-square test and the chi-square for 
linear trend for ordinal variables. Prevalence ratios (PRs) and 95% 
confidence intervals (CIs) were estimated from binomial regression 
models. The Kruskal-Wallis test was used to compare units of blood 
in each of the 3 Child-Pugh (C-P) grades. For all analyses, a p-value 
<0.05 and 95% CI that did not span unity were considered the 
thresholds of statistical significance.
Results
The 448 patients evaluated included 349 men and 99 women of 
median age 50 years (range 24 - 87); 54 were C-P grade A, 179 
were C-P grade B and 215 were C-P grade C when assessed on first 
hospital admission (Table 1). A blood transfusion was required by 
330 patients during the initial admission. Balloon tamponade with 
a Sengstaken-Blakemore or Minnesota tube was used in 70 patients 
and a vasopressin or octreotide infusion was used in 78 (Table 1);  in 
28, both a balloon tube and vasopressin were used. Compared with 
grade B patients, significantly more C-P grade C patients required a 
major blood transfusion (7 or more units), the use of balloon tube 
and vasopressin or octreotide to control variceal bleeding (Table 
1). Median hospital stay for the 355 patients who survived the first 
admission was 7 days (range 1 - 39).
All 448 patients underwent emergency endoscopy which confirmed 
oesophageal varices as the source of bleeding. In 440/448 patients, 
endoscopic intervention was used to control variceal bleeding at the 
index endoscopy session; 349 had sclerotherapy (median volume 
14 ml, range 1 - 40) as the initial endoscopic intervention and 86 
had endoscopic band ligation of varices (median 5 bands, range 
Table 1.  Child-Pugh grade, blood transfusion, balloon tube and vasopressin requirements to control acute variceal bleeding 
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Balloon tamponade 2 (3.7) 22 (12.3) 46 (21.4) 70 (15.6) 12.8 (2) 0.002
Vasopressin/octreotide 2 (3.7) 24 (13.4) 52 (24.2) 78 (17.4) 15.9 (2) <0.001
*Kruskal-Wallis test.
†Chi-square test (degrees of freedom).
Fig. 1. Rebleeding according to Child-Pugh score.
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1 - 10). Five patients had both endoscopic banding and injection 
sclerotherapy during the first endoscopy session in an attempt to 
control variceal bleeding. In 394 (87.9%) patients, control of variceal 
bleeding using endoscopic intervention alone was regarded as 
adequate haemostasis; in 8 (1.8%) variceal bleeding was profuse and 
visibility obscured, preventing safe endoscopic intervention and a 
Sengstaken balloon tube was inserted to control bleeding, followed 
by repeat endoscopy 12 hours later. In 46 (10.3%) patients who 
had initial endoscopic intervention, the endoscopist was concerned 
about the adequacy of the intervention and placed a Sengstaken 
tube on completion of the procedure. A total of 54 (12.1%) patients 
thus had a Sengstaken tube placed during treatment of the initial 
bleed. In 8 (1.8%) patients, variceal bleeding persisted despite 
pharmacological and endoscopic therapy and balloon tamponade. 
A total 805 endoscopic treatments were performed during the index 
hospital admission in the 448 patients, including 556 emergency and 
249 elective procedures. 
Within 24 hours of the index intervention, 15 (3.3%) patients 
underwent urgent repeat endoscopy because of continued (n=8) or 
early (n=7) rebleeding. A further 61 (13.6%) rebled after 24 hours 
and required further emergency endoscopic intervention to achieve 
definitive variceal haemostasis (Fig. 1). Six patients required a 
transjugular intrahepatic portosystemic shunt (TIPS) as a salvage 
procedure for uncontrolled bleeding during the index admission; 2 
died of multi-organ failure. A further 12 required a TIPS because of 
refractory variceal bleeding on subsequent admission. There was a 
significant upward trend in the proportion of rebleeding according 
to C-P grade (p<0.001) (Table 2): 26 (11.2%) of the 233 patients in 
grades A and B rebled compared with 50 (23.5%) of the 215 patients 
in grade C (PR=6.3, 95% CI 1.58 - 25.00, p<0.009). 
Ninety-three (20.8%) patients died during the initial hospital 
admission (Table 3). There was a strong correlation between mortality 
and C-P score (rs,=0.97, p<0.001): 74% and 100% mortality among 
patients with a C-P score of 14 and 15, respectively (Fig. 2). Median 
time to death was 7 days (range 0 - 52). There was a total mortality of 
64 (14.3%) during the first 2 weeks (Fig. 3), with 23 (5.1%) patients 
dying within 24 hours of admission and 41 within 5 days. No C-P 
grade A patients died, 16 grade B patients died, and 77 grade C 
patients died. Liver failure was the most common cause of death 
in 40 patients. Eleven patients died of liver and renal failure and 8 
died of pneumonia and respiratory failure. Death in 33 patients was 
a consequence of continued or recurrent variceal bleeding. Survival 
during the initial hospital admission in C-P grade A patients was 
100%, in grade B patients 91.1%, and in grade C patients 64.2% (Fig. 
3). Significantly more grade C patients than grade B patients died 
(PR=4.0, 95% CI 2.4 - 6.6, p<0.001) (Table 3).
Minor sclerotherapy and banding side-effects were common after 
acute intervention for bleeding, including dysphagia, transient fever, 
pulmonary atelectasis, pleural effusions and oesophageal mucosal 
ulceration. Eight (1.8%) patients had life-threatening complications 
after sclerotherapy, 3 developed a deep ulcer with a contained 
oesophageal perforation at the injection site, and a free oesphageal 
perforation occurred in 5 patients as a complication of emergency 
sclerotherapy during active variceal bleeding. Four of the 5 patients 
with sclerotherapy-induced perforations died, 3 due to recurrent 
variceal bleeding and 1 as a result of progressive liver and renal 
failure.
Discussion 
Endoscopy is essential in the modern multidisciplinary management 
of variceal bleeding.4 This study demonstrated that endoscopic therapy 
was effective in controlling the initial acute variceal bleed and that 
ultimate survival was influenced by rebleeding and underlying liver 
reserve. However, despite urgent endoscopic and pharmacological 
therapy, variceal bleeding is reported to recur in up to 20% of patients 
after initial endoscopic intervention.10 Early variceal rebleeding also 
significantly increases the risk of death within 6 weeks of the initial 
bleed.3,7,10 Prevention of rebleeding is a crucial element of management, 
considering the frequency of rebleeding after initial control.9 The 
lack of a universally implemented definition of failure of secondary 
prophylaxis has resulted in differences in the published incidence 
of rebleeding. This has hampered the interpretation of outcomes 
Fig. 2. Mortality according to Child-Pugh score.
Fig. 3. Hospital deaths (days 1 - 14).





n (%) PR p-value 95% CI
A 54 2 (3.7) - - -
B 179 24 (13.4) 3.6 0.074 0.88 - 14.83
C 215 50 (23.3) 6.3 0.009 1.58 - 25.0





n (%) PR p-value 95% CI
A 54 0 (0) - - -
B 179 16 (8.9) - - -
C 215 77 (35.8) 4.0 <0.001 2.43 - 6.61
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research and hindered accurate comparisons. We demonstrated that, 
although initial endoscopic intervention controlled acute variceal 
bleeding in 98.2% of patients, 17% rebled during the index hospital 
admission. The rebleeding rate in our study is lower than the 21% 
and 26% reported by others,16,17 despite our strictly observed and 
prospectively documented definition of rebleeding and the high-risk 
alcoholic cirrhotic cohort.
Evidence suggests that liver decompensation is a reliable predictor 
of rebleeding and mortality. Severity of liver disease, quantified as C-P 
and Meld scores or as individual components, is widely recognised as 
a robust independent predictor of early failure of bleeding control.3,7,8 
Active bleeding at initial endoscopy is an important risk factor for 
early failure in several studies.3,7,8 The highest mortality occurs during 
the first bleed. As in previous studies,5,8 our data confirmed that the 
first 5 days after admission represent the most crucial time period 
for determining prognosis (41 of 93 deaths occurred during this 
time). Up to one-third of deaths related to acute variceal bleeding 
are secondary to uncontrolled or recurrent bleeding, and most of the 
remaining cases are due to sepsis and liver and renal failure.1,2,4 The 
risk of death after acute variceal bleeding shows an evolution similar 
to that of rebleeding, peaking during the first 24 hours, and declining 
after 5 days and returning to the baseline after 6 weeks.16 
Our observations and those of others show that the efficacy of 
endoscopic intervention in controlling acute oesophageal variceal 
bleeding and mortality from bleeding are closely related to the 
severity of the underlying liver disease.3,5,8 As anticipated, mortality 
in our study increased exponentially as liver reserve diminished. 
There were no deaths in C-P grade A patients and, in this cohort 
with preserved liver function, early mortality was not influenced 
by the severity of the bleeding episode. An earlier study10 and the 
current data demonstrated that C-P grade C patients, who have the 
least hepatic reserve, were more likely to have a major bleed and 
require pitressin or octreotide and balloon tamponade in addition 
to sclerotherapy to control acute bleeding. Our study shows that 
in this high-risk group of alcoholic cirrhotic patients with liver 
decompensation aggravated by a significant variceal bleed, despite 
successful endoscopic control of the bleeding, progressive liver failure 
ensued with high mortality rates, especially in patients with C-P 
scores exceeding 13, who had a greater than 80% mortality.
This study had several limitations. The management of variceal 
bleeding has substantially advanced since the inception of the 
study, e.g. the use of variceal ligation in favour of sclerotherapy, 
improved pharmacotherapy with the replacement of vasopressin 
with octreotide, routine antibiotic prophylaxis, and enhanced critical 
care. These changes will not have influenced data analysis, as this 
was a longitudinal cohort study. A major strength was that the 
study was conducted in a single centre in a defined population of 
consecutive patients; this eliminates potential bias based on selection 
of treatment. To provide the highest possible level of uniformity and 
to minimise differences in the zero-time entry, only patients who 
received their initial and subsequent treatment in our unit were 
studied. The study design minimised possible bias that may have 
arisen from patient selection, referral practices and local variations 
in treatment strategies. Using rebleeding and death as the main 
outcomes provided consistent and objective end-points. The study 
robustness was enhanced by the prospective data collection, complete 
follow-up and restriction of subjects to those with alcohol-induced 
cirrhosis. The inception cohort were at a well-defined stage in the 
course of cirrhosis, providing an homogenous study population 
and avoiding the error of over-fitting which has influenced previous 
studies. 
Conclusions
This study has established the outcome of decompensated alcoholic 
cirrhotic patients after the index variceal bleed. Consistent with 
previous studies,3,7,8 we found that the C-P score was an efficient tool 
for predicting overall in-hospital mortality. We established that C-P 
grade A patients respond well to current therapies, with no deaths. 
However, despite recent improvement in overall survival, mortality 
remains high in C-P grade C patients, who die from early rebleeding 
or subsequently from the detrimental systemic consequences that 
lead to progressive liver function deterioration. While this study 
demonstrated that endoscopic management is effective in controlling 
the initial bleed in alcoholic cirrhotic patients, rebleeding occurs 
in up to 20% of patients, some of whom may require rescue 
intervention. These results have important prognostic implications 
and show that the C-P score does not effectively predict failure to 
control bleeding. Knowledge of predictive factors to identify those 
at risk of early rebleeding could allow the effective triage of patients 
to implement the early use of aggressive salvage therapy. The paucity 
of accurate and robust data predicting the likelihood of variceal 
rebleeding warrants further research to define the optimal evidence-
based standard of care in this high-risk cohort of patients. 
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